Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HERTHENA-Breast04
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- NCT07060807 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on HERTHENA-Breast04 (patritumab deruxtecan, pegylated liposomal doxorubicin and 5 more in Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERTHENA-Breast04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Patritumab deruxtecan; Paclitaxel; Nab-paclitaxel; Capecitabine; Pegylated liposomal doxorubicin; Trastuzumab deruxtecan; Rescue Medication
- Arms
- Patritumab Deruxtecan · Experimental
- Treatment of Physician's Choice · Active comparator
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Daiichi Sankyo
- Start
- Jul 21, 2025
- Primary completion
- Jul 14, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT07060807 · updated Oct 23, 2026